Received Mar 7, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HEPA | HEP A (VAQTA) | MERCK & CO. INC. | 1 | Y008483 | — |
| HIBV | HIB (PEDVAXHIB) | MERCK & CO. INC. | 3 | Y006393 | — |
| PNC15 | PNEUMO (VAXNEUVANCE) | MERCK & CO. INC. | 4 | Y005465 | — |
No additional AE cases; VFC immunization coordinator calling to report T/E for VAQTA , PEDVAX HIB , VAXNEUVANCE that was administered; This spontaneous report was received from a nurse and refers to a patient of unknown age and gender. The patient's medical history, concurrent conditions and concomitant therapies were not reported. On 18-Feb-2025, a temperature excursion (TE) occurred (temperature: 32.0F; time frame: 2 hours 12 minutes 0 seconds). There was no previous temperature excursion. On 21-Feb-2025, following the TE, the patient was vaccinated with the fourth dose of with Pneumococcal 15-valent Conjugate Vaccine (VAXNEUVANCE) lot #Y005465, expiration date reported as and upon internal review confirmed to be: 08-Jan-2027 (exact dose and route of administration were not reported), with the first dose of Varicella Virus Vaccine Live (Oka-Merck) (VARIVAX) lot #Y008483, expiration date reported as and upon internal review confirmed to be: 26-Nov-2025 (exact dose and route of administration were not reported), and with the third dose of Haemophilus b Conjugate Vaccine (Meningococcal Protein Conjugate) (LIQUID PEDVAX HIB) lot #Y006393, expiration date reported as and upon internal review confirmed to be: 07-Nov-2026 (exact dose and route of administration were not reported) (product storage error). All vaccines were administered for prophylaxis. No additional adverse event (AE) cases were noted (no adverse event). No product quality complaint (PQC) was reported.